Applied Therapeutics Takes Strong Swipe At SORD With Govorestat

16 Feb 2024

Govorestat could soon be filed for a second indication after impressing as a potential treatment for SORD deficiency, one of the most common forms of recessive hereditary neuropathy for which there are no approved therapies.

Shoshana Shendelman • Source: Applied Therapeutics

Having recently submitted govorestat on both sides of the Atlantic for galactosemia, Applied Therapeutics Inc. will be knocking on the regulators' doors again soon on the back of more impressive data, this time evaluating the drug for sorbitol dehydrogenase (SORD) deficiency.

The New York-headquartered biotech has unveiled positive interim 12-month results from the ongoing Phase III INSPIRE trial evaluating once-daily oral...